Literature DB >> 18479429

Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect.

P V Jenkins1, H Egan, C Keenan, E O'Shea, O P Smith, B Nolan, B White, J O'Donnell.   

Abstract

Haemophilia B generally arises as a result of unique mutations within the F9 gene and occurs with a prevalence of approximately one case per 30 000 males worldwide. The population prevalence of haemophilia B in Ireland at one per 12 500 males is particularly high. To identify the mutations responsible for haemophilia B and to define the biological basis underlying the increased prevalence in the Irish population, we performed sequence analysis of the F9 gene in 51 apparently unrelated kindred. In 18 kindred with severe or moderate haemophilia B, we identified 14 different mutations; these occurred throughout the F9 gene and included small deletions, missense, non-sense and splice-site mutations and included four novel candidate mutations. In contrast to the variety of different causative mutations with moderate or severe haemophilia B, we found three common mutations accounted for 83% (24/29) of Irish kindred with mild haemophilia B. The mutation n-6 G>A in the promoter region of F9 (which results in the characteristic haemophilia B Leyden phenotype) was found in 10 unrelated kindred. The mutation C>T 30933 in exon 8 (Ala271Val) was identified in a further 10 apparently unrelated kindred. Finally, 10430 G>A mutation (Gly60Ser) was observed in four different kindred. Haplotype analysis was performed on the index cases with the most common mutations and supported the hypothesis that the increased population prevalence of mild haemophilia B in the Irish population arose as a result of founder effect rather than an increased incidence of de-novo F9 mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479429     DOI: 10.1111/j.1365-2516.2008.01765.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.

Authors:  Muhammad Tariq Masood Khan; Arshi Naz; Jawad Ahmed; Tahir Shamsi; Shariq Ahmed; Nisar Ahmed; Ayisha Imran; Nazish Farooq; Muhammad Tariq Hamayun Khan; Abid Sohail Taj
Journal:  Clin Appl Thromb Hemost       Date:  2017-07-28       Impact factor: 2.389

Review 2.  Recent advances in hemophilia B therapy.

Authors:  Sarena D Horava; Nicholas A Peppas
Journal:  Drug Deliv Transl Res       Date:  2017-06       Impact factor: 4.617

3.  Mutation analysis of a cohort of US patients with hemophilia B.

Authors:  Tengguo Li; Connie H Miller; Jennifer Driggers; Amanda B Payne; Dorothy Ellingsen; W Craig Hooper
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

Review 4.  Hemophilia B: molecular pathogenesis and mutation analysis.

Authors:  A C Goodeve
Journal:  J Thromb Haemost       Date:  2015-05-18       Impact factor: 5.824

5.  Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.

Authors:  Christoph Male; Nadine G Andersson; Anne Rafowicz; Ri Liesner; Karin Kurnik; Kathelijn Fischer; Helen Platokouki; Elena Santagostino; Hervé Chambost; Beatrice Nolan; Christoph Königs; Gili Kenet; Rolf Ljung; Marijke Van den Berg
Journal:  Haematologica       Date:  2021-01-01       Impact factor: 9.941

6.  Hemophilia management: Huge impact of a tiny difference.

Authors:  Fabienne Kloosterman; Anne-Fleur Zwagemaker; Amal Abdi; Samantha Gouw; Giancarlo Castaman; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.